IL201865A0 - Rna beta-catenin antagonist compounds, compositions comprising the same and uses thereof - Google Patents

Rna beta-catenin antagonist compounds, compositions comprising the same and uses thereof

Info

Publication number
IL201865A0
IL201865A0 IL201865A IL20186509A IL201865A0 IL 201865 A0 IL201865 A0 IL 201865A0 IL 201865 A IL201865 A IL 201865A IL 20186509 A IL20186509 A IL 20186509A IL 201865 A0 IL201865 A0 IL 201865A0
Authority
IL
Israel
Prior art keywords
compositions
same
antagonist compounds
catenin antagonist
rna
Prior art date
Application number
IL201865A
Other languages
English (en)
Original Assignee
Santaris Pharma As
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma As, Enzon Pharmaceuticals Inc filed Critical Santaris Pharma As
Publication of IL201865A0 publication Critical patent/IL201865A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL201865A 2007-05-01 2009-11-01 Rna beta-catenin antagonist compounds, compositions comprising the same and uses thereof IL201865A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91537107P 2007-05-01 2007-05-01
US2324408P 2008-01-24 2008-01-24
PCT/EP2008/055365 WO2008132234A2 (en) 2007-05-01 2008-04-30 Rna antagonist compounds for the modulation of beta-catenin

Publications (1)

Publication Number Publication Date
IL201865A0 true IL201865A0 (en) 2011-08-01

Family

ID=39926160

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201865A IL201865A0 (en) 2007-05-01 2009-11-01 Rna beta-catenin antagonist compounds, compositions comprising the same and uses thereof

Country Status (15)

Country Link
US (4) US20090005335A1 (enExample)
EP (1) EP2152879B1 (enExample)
JP (2) JP2010524486A (enExample)
KR (1) KR20100024399A (enExample)
CN (1) CN101842483A (enExample)
AU (1) AU2008244211B2 (enExample)
CA (1) CA2685444A1 (enExample)
DK (1) DK2152879T3 (enExample)
EA (1) EA018986B1 (enExample)
ES (1) ES2399371T3 (enExample)
IL (1) IL201865A0 (enExample)
MX (1) MX2009011878A (enExample)
NZ (1) NZ581200A (enExample)
TW (1) TW200848077A (enExample)
WO (1) WO2008132234A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152879B1 (en) * 2007-05-01 2012-11-14 Santaris Pharma A/S Rna antagonist compounds for the modulation of beta-catenin
EP2490767A4 (en) 2009-07-15 2013-02-13 Santaris Pharma As GLI2 TARGETING TARGET ANTAGONIST FOR THE TREATMENT OF LEUKEMIA
ES2873893T3 (es) 2010-07-06 2021-11-04 Dicerna Pharmaceuticals Inc Métodos y composiciones para la inhibición específica de beta-catenina por RNA bicatenario
EP2638163B1 (en) 2010-11-12 2017-05-17 The General Hospital Corporation Polycomb-associated non-coding rnas
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
JP2014533280A (ja) * 2011-11-11 2014-12-11 サンタリス ファーマ アー／エスＳａｎｔａｒｉｓ Ｐｈａｒｍａ Ａ／Ｓ ベータ−カテニン発現の調節のための化合物およびその使用
HK1205758A1 (en) * 2012-01-09 2015-12-24 Novartis Ag Rnai agents to treat beta-catenin related diseases
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
KR102028784B1 (ko) 2012-05-16 2019-10-04 트랜슬레이트 바이오 인코포레이티드 유전자 발현을 조절하기 위한 조성물 및 방법
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
BR112015010116A2 (pt) 2012-11-15 2017-08-22 Roche Innovation Ct Copenhagen As COMPOSTOS CONJUGADOS ANTI-SENTIDO ANTI-ApoB
HK1215718A1 (zh) * 2013-01-30 2016-09-09 F. Hoffmann-La Roche Ag Lna寡核苷酸碳水化合物缀合物
SG10201803157XA (en) 2013-05-01 2018-05-30 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
US9506030B2 (en) 2013-05-01 2016-11-29 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
EP3036602A4 (en) 2013-08-22 2017-04-12 Hewlett-Packard Development Company, L.P. Projective computing system
TWI657755B (zh) * 2013-12-30 2019-05-01 Philip Morris Products S. A. 包含隔熱可燃熱源之煙品
CN106470699A (zh) 2014-02-03 2017-03-01 耶路撒冷希伯来大学的益生研究开发有限公司 使用酪蛋白激酶i抑制剂以消耗干细胞的用途
WO2016070060A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
EP3271460A4 (en) 2015-03-17 2019-03-13 The General Hospital Corporation RNA INTERACTOM OF POLYCOMB REPRESSIVE COMPLEX 1 (PRC1)
WO2018093919A1 (en) * 2016-11-15 2018-05-24 City Of Hope Methods for intracellular delivery and enhanced gene targeting
EP3790972A1 (en) 2018-05-08 2021-03-17 Regulus Therapeutics Inc. Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962029A (en) 1987-10-02 1990-10-09 Cetus Corporation Covalent oligonucleotide-horseradish peroxidase conjugate
US4914210A (en) 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
US6066500A (en) 1999-06-25 2000-05-23 Isis Pharmaceuticals Inc. Antisense modulation of Beta catenin expression
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US20030064384A1 (en) * 2001-04-02 2003-04-03 Mien-Chie Hung Beta-catenin is a strong and independent prognostic factor for cancer
US20030143586A1 (en) * 2001-10-12 2003-07-31 Qimin Chao Genetic hypermutability of plants for gene discovery and diagnosis
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
US9045518B2 (en) 2002-11-18 2015-06-02 Santaris Pharma A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
RU2394041C2 (ru) * 2003-04-13 2010-07-10 Энзон Фармасьютикалз, Инк. Полимерные олигонуклеотидные пролекарства
US20050136395A1 (en) * 2003-05-08 2005-06-23 Affymetrix, Inc Methods for genetic analysis of SARS virus
US20070009899A1 (en) * 2003-10-02 2007-01-11 Mounts William M Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
EP1931778A2 (en) 2005-09-15 2008-06-18 Santaris Pharma A/S RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-Bl00 EXPRESSION
JP5731115B2 (ja) 2006-05-05 2015-06-10 アイシス ファーマシューティカルズ， インコーポレーテッド 遺伝子発現を調節するための化合物および方法
AU2007296054B2 (en) 2006-09-15 2013-03-28 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
MX2009002856A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Conjugados polimericos que contienen porciones cargadas positivamente.
WO2008053314A2 (en) 2006-10-30 2008-05-08 Nokia Corporation Method, apparatus and system providing operator controlled mobility for user equipment
EP2152879B1 (en) * 2007-05-01 2012-11-14 Santaris Pharma A/S Rna antagonist compounds for the modulation of beta-catenin

Also Published As

Publication number Publication date
MX2009011878A (es) 2010-01-25
US7915401B2 (en) 2011-03-29
JP2010524486A (ja) 2010-07-22
US20110086902A1 (en) 2011-04-14
US20090005335A1 (en) 2009-01-01
US20090203137A1 (en) 2009-08-13
CN101842483A (zh) 2010-09-22
NZ581200A (en) 2012-04-27
AU2008244211B2 (en) 2014-08-21
WO2008132234A3 (en) 2009-05-07
EA018986B1 (ru) 2013-12-30
DK2152879T3 (da) 2013-02-18
US8039446B2 (en) 2011-10-18
WO2008132234A4 (en) 2009-07-09
ES2399371T3 (es) 2013-03-27
CA2685444A1 (en) 2008-11-06
KR20100024399A (ko) 2010-03-05
EP2152879A2 (en) 2010-02-17
WO2008132234A2 (en) 2008-11-06
EA200971013A1 (ru) 2010-04-30
EP2152879B1 (en) 2012-11-14
AU2008244211A1 (en) 2008-11-06
JP2014209915A (ja) 2014-11-13
TW200848077A (en) 2008-12-16
US20120004288A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
IL201865A0 (en) Rna beta-catenin antagonist compounds, compositions comprising the same and uses thereof
IL202038A0 (en) Rna antagonist compounds, compositions comprising the same and uses thereof
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
IL204621A0 (en) Bicyclic - ?? - amino acid derivatives, compositions comprising the same and uses thereof
IL212836A0 (en) Azaquinolinone derivatives, compositions comprising the same and uses thereof
IL241633A0 (en) History of benzodiazepines, preparations containing them and their uses
IL208744A0 (en) Nucleic acid-lipid particles, compositions comprising the same and uses thereof
IL230759A0 (en) Converted acyl anilide, the pharmaceutical composition containing it and its uses
SI2217578T1 (sl) (1,2,4)triazolo(1,5-a)piridinske in (1,2,4)triazolo(1,5-c)pirimidinske spojine in njihova uporaba
IL205880A0 (en) Aminoglycoside analogs, compositions comprising the same and uses thereof
IL205705A0 (en) Anti-influenza antibodies, compositions comprising the same and uses thereof
IL210722A0 (en) Benzazepine derivatives, compositions comprising the same and uses thereof
IL200846A0 (en) Oligomer-protease inhibitor conjugates, compositions comprising the same and uses thereof
IL212278A0 (en) Morpholinopurine derivatives, compositions comprising the same and uses thereof
IL210821A0 (en) Pyrazolopyridine kinase inhibitor compounds, compositions comprising the same and uses thereof
IL201064A0 (en) Janus kinase inhibitor compounds, compositions comprising the same and uses thereof
IL205057A0 (en) Pyrimidyl indoline compound, composition comprising the same and uses thereof
IL198510A0 (en) Tricyclic heteroaryl compounds, compositions comprising the same and uses thereof
IL200847A0 (en) Oligomer-antihistamine inhibitor conjugates, compositions comprising the same and uses thereof
IL207066A0 (en) Iap inhibitor compounds, compositions comprising the same and uses thereof
IL212906A0 (en) Triazolothiadiazole inhibitor compounds, compositions comprising the same and uses thereore
IL205966A0 (en) Oligomer-tricyclic conjugates, compositions comprising the same and uses thereof
GB0706077D0 (en) Methods, Compositions and uses thereof
IL206153A0 (en) Rna antagonist compounds for the modulation of pik3ca compositions comprising the same and uses thereof
IL236601A0 (en) Antibodies against cytomegalovirus, preparations containing them and their uses